developer, manufacturer and distributor of pharmaceuticals
Biopharmaceutical innovation and patent policy issues. Trademark legislative proposals. Bayh-Dole march-in rights policy issues. Issues related to appropriations and federal health programs; reimbursement issues; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2811, Limit, Save, Grow Act of 2023. Issues related to pharmaceutical IP and supply chain. Implementation of Tax Cuts and Jobs Act (P.L.115-97). Issues related to R&D tax credit; H.R.3938, Build It in America Act. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; Medicaid Proposed Rebate Rule. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, VICP Program, and insulin price cap; Animal Drug User Fee Reauthorization, H.R.5860, Making continuing appropriations for fiscal year 2024, and for other purposes; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
CPT - Copyright/Patent/Trademark BUD - Budget/Appropriations TRD - Trade (domestic/foreign) TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CROSSROADS STRATEGIES, LLC
800 North Capitol Street, NW, Suite 800, Washington, DC, 20002, US
CHERYL LYNN JAEGER BRITTANY JOHNSON HERNANDEZ JASON GLEASON JASON BENJAMIN VAN PELT MATHEW LAPINSKI JOHN GREEN CHERYL LYNN JAEGER BRITTANY JOHNSON HERNANDEZ JASON GLEASON JASON BENJAMIN VAN PELT MATHEW LAPINSKI JOHN GREEN CHERYL LYNN JAEGER BRITTANY JOHNSON HERNANDEZ JASON GLEASON JASON BENJAMIN VAN PELT MATHEW LAPINSKI JOHN GREEN CHERYL LYNN JAEGER BRITTANY JOHNSON HERNANDEZ JASON GLEASON JASON BENJAMIN VAN PELT MATHEW LAPINSKI JOHN GREEN CHERYL LYNN JAEGER BRITTANY JOHNSON HERNANDEZ JASON GLEASON JASON BENJAMIN VAN PELT MATHEW LAPINSKI JOHN GREEN CHERYL LYNN JAEGER BRITTANY JOHNSON HERNANDEZ JASON GLEASON JASON BENJAMIN VAN PELT MATHEW LAPINSKI JOHN GREEN